Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]
Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.
Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.
5 Rheumatology Headlines You Missed in December 2025
Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation
1.
Study recommends new grading system for invasive squamous cell carcinoma of the lung
2.
Bayer is transforming pharmaceutical research into women's health
3.
Ineffective medication can remove the "worst fear" of schizophrenia.
4.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
5.
A healthier lifestyle after bowel screening shown to prevent bowel cancer
1.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
2.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
3.
Everything You Need To Know About Splenic Infarction – Symptoms, Treatments, And Prevention
4.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
5.
Understanding Leiomyoma: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge